Hereditary cancer testing detects inherited mutations (like BRCA1/2) that raise cancer risk, helping with early prevention and personalized care.
Solid tumor testing examines a tumor’s genes
to guide diagnosis and treatment, identifying mutations for personalized therapies in
cancers like lung, colon, and breast.
utilizes advanced Next-Generation Sequencing (NGS) to analyze an extensive range of cancer-related genes and biomarkers in a single assay. By mapping a tumor’s unique genetic landscape, CGP aligns clinical findings with established guidelines and global trials to empower personalized, data-driven treatment strategies
While the BRCA test targets the BRCA1 and BRCA2 genes, it is only part of the story. Comprehensive genetic screening now evaluates additional high-risk genes associated with breast and ovarian cancers, providing a more complete assessment
of hereditary risk.
Our Comprehensive Breast and Ovarian Cancer Panel evaluates both well-established and emerging susceptibility genes, providing a complete genetic risk assessment for hereditary cancers
AI Website Generator